Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia

Dementia and Geriatric Cognitive Disorders

Volumn 40, Issue 1-2, 2015, Pages 54-62

  Rostgaard, Nina ^a   Waldemar, Gunhild ^a   Nielsen, Jørgen Erik ^a   Simonsen, Anja Hviid ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Alzheimer's disease; Amyloid ; Biomarkers; Cerebrospinal fluid; Diagnosis; Familial dementia; Frontotemporal dementia; Tau protein

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GAMMA SECRETASE; PRESENILIN 1; TAU PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SYSTEMATIC REVIEW; EARLY DIAGNOSIS; MUTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMANS; MUTATION; TAU PROTEINS;

EID: 84929676153     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000381828     Document Type: Review

References (64)

1. World Health Organization; Alzheimer's Disease International: Dementia: a public health priority. Geneva, World Health Organization, 2012.
2. Holtzman DM, Morris JC, Goate AM: Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011; 3: 77sr1.
3. Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD: The diagnosis of young-onset dementia. Lancet Neurol 2010; 9: 793-806.
4. Hales CM, Hu WT: From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int Rev Psychiatry 2013; 25: 210-220.
5. Humpel C: Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011; 29: 26-32.
6. Chintamaneni M, Bhaskar M: Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol 2012; 2012: 984786.
7. Ringman J, Gylys K, Medina L, Fox M: Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett 2011; 487: 287-292.
8. Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Maréchal L, Martinaud O, et al: The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebro-spinal fluid biomarkers. J Alzheimers Dis 2012; 30: 847-856.
9. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, et al: Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012; 69: 96-104.
10. Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, et al: Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 1-5.
11. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al: Clinical and biomarker changes in domi-nantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
12. Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Långström B, et al: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-236.
13. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al: Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014; 6: 226ra30.
14. Luedecke D, Becktepe JS, Lehmbeck JT, Finckh U, Yamamoto R, Jahn H, et al: A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease. Neurosci Lett 2014; 566: 115-119.
15. Testi S, Peluso S, Fabrizi GM, Antenora A, Russo CV, Pappatà S, et al: A novel PSEN1 mutation in a patient with sporadic early-onset Alzheimer's disease and prominent cerebellar ataxia. J Alzheimers Dis 2014; 41: 709-714.
16. Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, et al: Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry 2002; 52: 907-910.
17. Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, et al: Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis 2011; 8: 202-207.
18. Aoki M, Abe K, Oda N, Ikeda M, Tsuda T, et al: A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI. Neurology 1997; 48: 1118-1120.
19. 42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. J Alzheimers Dis 2012; 30: 605-616.
20. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, et al: Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008; 71: 85-92.
21. Antonell A, Balasa M, Oliva R, Lladó A, Bosch B, Fabregat N, et al: A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neurosci Lett 2011; 496: 40-42.
22. de Bot ST, Kremer HPH, Dooijes D, Verbeek MM: CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation. J Alzheimers Dis 2009; 17: 53-57.
23. Tiedt HO, Lueschow A, Winter P, Müller U: Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease. Neurosci Lett 2013; 544: 115-118.
24. Binetti G, Signorini S, Squitti R, Alberici A, Benussi L, Cassetta E, et al: Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol 2003; 54: 832-836.
25. Nikisch G, Hertel A, Kiessling B, Wagner T, Krasz D, Hofmann E, Wiedemann G: Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature. Eur J Med Res 2008; 13: 579-584.
26. Cohn-Hokke PE, Wong TH, Rizzu P, Breedveld G, van der Flier WM, Scheltens P, et al: Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. J Neurol 2014; 261: 2085-2092.
27. Uttner I, Kirchheiner J, Tumani H, Mottaghy FM, Lebedeva E, Ozer E, et al: A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. Eur J Neurol 2010; 17: 631-633.
28. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al: Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the prese-nilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056.
29. 42 levels precede cognitive decline. Neurology 2005; 65: 323-325.
30. Almkvist O, Axelman K, et al: Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179: 77-82.
31. Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, et al: Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 2010; 5: 2.
32. Portelius E, Fortea J, Molinuevo JL, Gustavsson MK, Andreasson U, Sanchez-Valle R: The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Mol Med Rep 2012; 5: 1111-1115.
33. Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, Batbayli M, et al: Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur J Neurol 2008; 15: 377-385.
34. Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, et al: Total tau and phos-phorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 2003;60: 1209-1213.
35. Tolboom N, Koedam E, et al: Dementia mimicking Alzheimer's disease owing to a tau mutation: CSF and PET findings. Alzheimer Dis Assoc Disord 2010; 24: 303-307.
36. Brouwers N, Nuytemans K, et al: Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 2007; 64: 1436-1446.
37. Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, et al: Cerebrospinal fluid biomarkers in progranulin mutations carriers. J Alzheimers Dis 2011; 27: 781-790.
38. Pietroboni A, Fumagalli G, et al: Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. J Alzheimers Dis 2011; 24: 253-259.
39. Suárez-Calvet M, Dols-Icardo O, Lladó A, Sánchez-Valle R, Hernández I, Amer G, et al: Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry 2014; 85: 684-691.
40. Wallon D, Rovelet-Lecrux A, Deramecourt V, Pariente J, Auriacombe S, Le Ber I, et al: Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebro-spinal fluid biomarkers. J Alzheimers Dis 2012; 32: 19-22.
41. Suhonen NM, Kaivorinne AL, Moilanen V, Bode M, Takalo R, Hänninen T, et al: Slowly progressive frontotem-poral lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. Neurocase 2015; 21: 85-89.
42. Saint-Aubert L, Sagot C, Wallon D, Hannequin D, Payoux P, Nemmi F, et al: A case of logopenic primary progressive aphasia with C9ORF72 expansion and cortical florbetapir binding. J Alzheimers Dis 2014; 42: 413-420.
43. Abbate C, Arosio B, Galimberti D, Nicolini P, Chiara LR, Rossi PD, et al: Phenotypic variability associated with the C9ORF72 hexanucleotide repeat expansion: a sporadic case of frontotemporal lobar degeneration with prodromal hyposmia and predominant semantic deficits. J Alzheimers Dis 2014; 40: 849-855.
44. Alzforum: Mutation database. http://www.alzforum.org/mutations.
45. Shen J, Kelleher RJ 3rd: The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 2007; 104: 403-409.
46. Gendron TF, Petrucelli L: The role of tau in neurodegeneration. Mol Neurodegener 2009; 4: 13.
47. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
48. Jakob-Roetne R, Jacobsen H: Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl 2009; 48: 3030-3059.
49. Simonsen AH, Bahl JMC, Danborg PB, Lindstrom V, Larsen SO, Grubb A, et al: Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 2013; 215: 234-240.
50. Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, et al: Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005; 196: 273-281.
51. Davidsson P, Sjögren M, Andreasen N, Lindbjer M, Nilsson CL, Westman-Brinkmalm A, et al: Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Mol Brain Res 2002; 109: 128-133.
52. Simonsen A, McGuire J, Podust VN, Hagnelius N-O, Nilsson TK, Kapaki E, et al: A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 2007; 24: 434-440.
53. ClinicalTrials.gov: Dominantly Inherited Alzheimer Network trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer's disease caused by a genetic mutation (DIAN-TU). 2012. https://www.clinicaltrials.gov/ct2/ show/NCT01760005?term=NCT01760005&rank=1 (accessed February 19, 2015).
54. ClinicalTrials.gov: Dominantly Inherited Alzheimer Network (DIAN). 2009. https://www.clinicaltrials.gov/ ct2/show/NCT00869817?term=NCT00869817&rank=1 (accessed February 19, 2015).
55. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al: Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013; 5: 48.
56. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-321.
57. Roche: Media release: Roche provides update on gantenerumab development programme. 2014. http://www. roche.com/media/store/releases/med-cor-2014-12-19b.htm.
58. Iovino M, Pfisterer U, Holton JL, Lashley T, Swingler RJ, Calo L, et al: The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. Acta Neuropathol 2014; 127: 283-295.
59. Ishida C, Kobayashi K, Kitamura T, Ujike H, Iwasa K, Yamada M: Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT R406W mutation presenting with a broad distribution of abundant senile plaques. Neuropathology 2015; 35: 75-82.
60. Popović M, Fabjan A, Mraz J, Magdić J, Glavać D, Zupan A, et al: Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions. Acta Neuro-pathol 2014; 128: 155-157.
61. Calvi A, Cioffi SMG, Caffarra P, Fenoglio C, Serpente M, Pietroboni AM, et al: The novel GRN g.1159-1160delTG mutation is associated with behavioral variant frontotemporal dementia. J Alzheimers Dis 2015; 44: 277-282.
62. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G: Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008; 71: 1235-1239.
63. Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, et al: Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol 2010; 69: 1191-1200.
64. Lannfelt L, Basun H, Wahlund L, et al: Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1995; 1: 829-832.